MicroRNAs in breast cancer development and treatment

Cancer Treatment Reviews

Volumn 40, Issue 5, 2014, Pages 595-604

  Serpico, Danila ^a   Molino, Leonardo ^a   Di Cosimo, Serena ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Biomarkers; Breast cancer; MicroRNAs; Targeted therapy

Indexed keywords

AZACITIDINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; MICRORNA 100; MICRORNA 107; MICRORNA 122; MICRORNA 125B; MICRORNA 126; MICRORNA 132; MICRORNA 141; MICRORNA 143; MICRORNA 145; MICRORNA 146A; MICRORNA 155; MICRORNA 16; MICRORNA 182; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; MICRORNA 210; MICRORNA 22; MICRORNA 29B; MICRORNA 31; MICRORNA 375; MICRORNA 9; PACLITAXEL; TRASTUZUMAB;

BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; GENE SILENCING; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SYSTEMATIC REVIEW;

BIOMARKERS; BREAST CANCER; MICRORNAS; TARGETED THERAPY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICRORNAS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84898463063     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.11.002     Document Type: Review

References (101)

1. Malvezzi M., Bertuccio P., Levi F., La Vecchia C., Negri E. European cancer mortality predictions for the year 2013. Ann Oncol 2013, 00:1-9. 10.1093/annonc/mdt010.
2. Breast Cancer Facts and Figures 2013-2014 2013, American Cancer Society, American Cancer Society Inc., Atlanta.
3. Peto R., Davies C., Godwin J., Gray R., Pan H.C., et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379(9814):432-444. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Epub 2011 Dec 5. 10.1016/S0140-6736(11)61625-5.
4. Meisel J.L., Domchek S.M., Vonderheide R.H., Giobbie-Hurder A., Lin N.U., Winer E.P., et al. Quality of life in long-term survivors of metastatic breast cancer. Clin Breast Cancer 2012, 12(2):119-126. 10.1016/j.clbc.2012.01.010.
5. Cardoso F., Costa A., Norton L., Cameron D., Cufer T., Fallowfield L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21(3):242-252. Epub 2012 Mar 16. 10.1016/j.breast.2012.03.003.
6. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294(5543):853-858.
7. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65(16):7065-7070.
8. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120(1):15-20.
9. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
10. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10:704-714.
11. Brennecke J., Hipfner D.R., Stark A., Russell R.B., Cohen S.M. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 2003, 113:25-36.
12. Avril-Sassen S., Goldstein L.D., Stingl J., Blenkiron C., Le Quesne J., Spiteri I., et al. Characterisation of microRNA expression in post-natal mouse mammary gland development. BMC Genomics 2009, 10:548.
13. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103(7):2257-2261. Epub 2006 Feb 3.
14. Huang G.L., Zhang X.H., Guo G.L., Huang K.T., Yang K.Y., Shen X., et al. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 2009, 21(3):673-679.
15. Walter B.A., Gómez-Macias G., Valera V.A., Sobel M., Merino M.J. MiR-21 expression in pregnancy-associated breast cancer: a possible marker of poor prognosis. J Cancer 2011, 7(2):67-75.
16. Ota D., Mimori K., Yokobori T., Iwatsuki M., Kataoka A., Masuda N., et al. Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. Int J Oncol 2011, 38(4):955-962. Epub 2011 Jan 26. 10.3892/ijo.2011.926.
17. Si M.L., Zhu S., Wu H., Lu Z., Wu F., Mo Y.Y. MiR-21-mediated tumor growth. Oncogene 2007, 26:2799-2803.
18. Frankel L.B., Christoffersen N.R., Jacobsen A., Lindow M., Krogh A., Lund A.H. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008, 283(2):1026-1033. Epub 2007 Nov 8.
19. Zhu S., Si M.L., Wu H., Mo Y.Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007, 282(19):14328-14336.
20. Hossain A., Kuo M., Saunders G. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of aib1 mRNA. Mol Cell Biol 2006, 26(21):8191-8201. Epub 2006 Aug 28.
21. Kato M., Paranjape T., Muller R.U., Nallur S., Gillespie E., Keane K., et al. The miR-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene 2009, 28:2419-2424.
22. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., et al. P53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007, 17:1298-1307.
23. Tsuchiya Y., Nakajima M., Takagi S., Taniya T., Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 2006, 66(18):9090-9098.
24. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007 Dec 14, 131(6):1109-1123.
25. Song Su Jung, Poliseno Laura, Song Min Sup, Ala Ugo, Webster Kaitlyn, Ng Christopher, et al. microRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013, 154(2):311-324. 10.1016/j. cell.2013.06.026.
26. Martello G., Rosato A., Ferrari F., Manfrin A., Cordenonsi M., Dupont S., et al. A microRNA targeting dicer for metastasis control. Cell 2010, 141(7):1195-1207. 10.1016/j.cell.2010.05.017.
27. Huang Q., Gumireddy K., Schrier M., et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008, 10:202-210.
28. Chen D., Sun Y., Wei Y., Zhang P., Rezaeian A.H., Teruya-Feldstein J., et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med 2012, 18(10):1511-1517. Epub 2012 Sep 23. 10.1038/nm.2940.
29. Anand S., Majeti B.K., Acevedo L.M., Murphy E.A., Mukthavaram R., Scheppke L., et al. microRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 2010, 16(8):909-914.
30. Yu Z., Willmarth N.E., Zhou J., Katiyar S., Wang M., Liu Y., et al. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci USA 2010, 107(18):8231-8236. Published online 2010 April 19. 10.1073/pnas.1002080107 PMCID: PMC2889540.
31. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10(5):593-601. Epub 2008 Mar 30. 10.1038/ncb1722.
32. Iorio M.V., Casalini P., Piovan C., Di Leva G., Merlo A., Triulzi T., et al. MicroRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009, 69(6):2195-2200. Epub 2009 Mar 10. 10.1158/0008-5472.CAN-08-2920.
33. Scott G., Goga A., Bhaumik D., Berger C., Sullivan C., Benz C. Coordinate suppression of erbb2 and erbb3 by enforced expression of micro-RNA mir-125a or mir-125b. J Biol Chem 2007, 282:1479-1486.
34. Meister G., Landthaler M., Patkaniowska A., Dorsett Y., Teng G., Tuschl T. Human argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 2004, 15:185-197.
35. Hutvagner G., Zamore P.D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002, 297:2056-2060.
36. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008, 9(6):582-589. Epub 2008 May 16. 10.1038/embor.2008.74.
37. Bhaumik D., Scott G.K., Schokrpur S., Patil C.K., Campisi J., Benz C.C. Expression of microRNA-146 suppresses NF-kB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008, 27:5643-5647.
38. Hurst D.R., Edmonds M.D., Scott G.K., Benz C.C., Vaidya K.S., Welch D.R. Breast cancer metastasis suppressor 1, BRMS1, up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009, 69:1279-1283.
39. Tavazoie S.F., Alarcon C., Oskarsson T., et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451(7175):147-152.
40. Valastyan S., Reinhardt F., Benaich N., et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009, 137:1032-1046.
41. Guo X., Wu Y., Hartley R. MicroRNA-125a represses cell growth by targeting hur in breast cancer. RNA Biol 2009, 6:575-583.
42. Hofmann M.H., Heinrich J., Radziwill G., Moelling K. A short hairpin DNA analogous to miR-125b inhibits C-Raf expression, proliferation, and survival of breast cancer cells. Mol Cancer Res 2009, 7(10):1635-1644. Epub 2009 Oct 13. 10.1158/1541-7786.MCR-09-0043.
43. Reddy S.D., Ohshiro K., Rayala S.K., Kumar R. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res 2008, 68(20):8195-8200.
44. Reddy S.D., Pakala S.B., Ohshiro K., Rayala S.K., Kumar R. MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Res 2009, 69(14):5639-5642. Epub 2009 Jul 7. 10.1158/0008-5472.CAN-09-0898.
45. Chou J., Lin J.H., Brenot A., Kim J.W., Provot S., Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol 2013, 15(2):201-213. Epub 2013 Jan 27. 10.1038/ncb2672.
46. Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010, 56(11):1733-1741. Epub 2010 Sep 16. 10.1373/clinchem.2010.147405.
47. Accerbi M., Schmidt S.A., De Paoli E., Park S., Jeong D.H., Green P.J. Methods for isolation of total RNA to recover miRNAs and other small RNAs from diverse species. Methods Mol Biol 2010, 592:31-50. 10.1007/978-1-60327-005-2_3.
48. Cronin M., Pho M., Dutta D., et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004, 164:35-42.
49. Válóczi A., Hornyik C., Varga N., Burgyán J., Kauppinen S., Havelda Z. Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes. Nucleic Acids Res 2004, 32(22):e175. Published online 2004 December 14. 10.1093/nar/gnh171.
50. Thomson J.M., Parker J., Perou C.M., Hammond S.M. A custom microarray platform for analysis of microRNA gene expression. Nat Methods 2004, 1(1):47-53. Epub 2004 Sep 29.
51. Babak T., Zhang W., Morris Q., Blencowe B.J., Hughes T.R. Probing microRNAs with microarrays: tissue specificity and functional inference. RNA 2004, 10(11):1813-1819.
52. Sempere L.F., Preis M., Yezefski T., et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered microRNA expression in solid tumors. Clin Cancer Res 2010, 16:4246-4255.
53. Shi R., Chiang V.L. Facile means for quantifying microRNA expression by real-time PCR. Biotechniques 2005, 39(4):519-525.
54. Jiang J., Lee E.J., Gusev Y., Schmittgen T.D. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 2005, 33(17):5394-5403. Print 2005.
55. Raymond C.K., Roberts B.S., Garrett-Engele P., Lim L.P., Johnson J.M. Simple, quantitative primer-extension PCR assay for direct monitoring of microRNAs and short-interfering RNAs. RNA 2005, 2005(11):1737-1744. 10.1261/rna.2148705.
56. Chen C., Ridzon D.A., Broomer A.J., Zhou Z., Lee D.H., Nguyen J.T., et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005, 33(20):e179.
57. Mestdagh P., Feys T., Bernard N., Guenther S., Chen C., Speleman F., et al. High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 2008, 36(21):e143. Epub 2008 Oct 21. 10.1093/nar/gkn725.
58. Blenkiron C., Goldstein L.D., Thorne N.P., Spiteri I., Chin S.F., Dunning M.J., et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007, 8(10):R214.
59. Mattie M.D., Benz C.C., Bowers J., et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006, 5:24.
60. Heneghan H.M., Miller N., Lowery A.J., Sweeney K.J., Newell J., Kerin M.J. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010, 251:499-505.
61. Zhu W., Qin W., Atasoy U., Sauter E.R. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2009, 2:89.
62. Wu X., Somlo G., Yu Y., Palomares M.R., Li A.X., Zhou W., et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med 2012, 8(10):42. 10.1186/1479-5876-10-42.
63. Shi W., Gerster K., Alajez N.M., Tsang J., Waldron L., Pintilie M., et al. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res 2011, 71:2926. EpubMarch 10, 2011. 10.1158/0008-5472.CAN-10-3369.
64. Roth C., Rack B., Müller V., Janni W., Pantel K., Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010, 12:R90. 10.1186/bcr2766.
65. Liang Z., Wu H., Xia J., Li Y., Zhang Y., Huang K., et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010, 79(6):817-824. Epub 2009 Oct 31. 10.1016/j.bcp.2009.10.017.
66. Kovalchuk O., Filkowski J., Meservy J., Ilnytskyy Y., Tryndyak V.P., Chekhun V.F., et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008, 7(7):2152-2159. 10.1158/1535-7163.MCT-08-0021.
67. Mei M., Ren Y., Zhou X., Yuan X.B., Han L., Wang G.X., et al. Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat 2010, 9(1):77-86.
68. Zhou M., Liu X., Zhao Y., Ding Y., Liu H., Xi Y., et al. MicroRNA-125B confers the resistance to paclitaxel through suppression of pro-apoptotic BCL-2 antagonist killer (BAK 1) expression. J Biol Chem 2007, 285(28):21496-21507. Epub May 11 2010. 10.1074/jbc.M109.083337.
69. Climent J., Dimitrow P., Fridlyand J., Palacios J., Siebert R., Albertson D.G., et al. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res 2007, 67(2):818-826. 10.1158/0008-5472.CAN-06-3307.
70. Miller T.E., Ghoshal K., Ramaswamy B., Roy S., Datta J., Shapiro C.L., et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008, 283(44):29897-29903. Epub 2008 Aug 15. 10.1074/jbc.M804612200.
71. Rao X., Di Leva G., Li M., Fang F., Devlin C., Hartman-Frey C., et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011, 30(9):1082-1097. Epub 2010 Nov 8. 10.1038/onc.2010.487.
72. Cittelly D.M., Das P.M., Salvo V.A., Fonseca J.P., Burow M.E., Jones F.E. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 2010, 31(12):2049-2057. Epub 2010 Sep 27. 10.1093/carcin/bgq192.
73. Masri S., Liu Z., Phung S., Wang E., Yuan Y.C., Chen S. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat 2010, 124(1):89-99. Epub 2010 Jan 7. 10.1007/s10549-009-0716-3.
74. Rodríguez-González F.G., Sieuwerts A.M., Smid M., Look M.P., Meijer-van Gelder M.E., de Weerd V., et al. MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 2011, 127(1):43-51. Epub 2010 May 19. 10.1007/s10549-010-0940-x.
75. Chen H., Sun J.G., Cao X.W., Ma X.G., Xu J.P., Luo F.K., et al. Preliminary validation of ERBB2 expression regulated by miR-548d-3p and miR-559. Biochem Biophys Res Commun 2009, 385(4):596-600. Epub 2009 May 30. 10.1016/j.bbrc.2009.05.113.
76. Gong C., Yao Y., Wang Y., Liu B., Wu W., Chen J., et al. Up-regulation of miR-21mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2011, 286(21):19127-19137. Epub 2011 Apr 6. 10.1074/jbc.M110.216887.
77. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011, 13(4):423-433. Epub 2011 Mar 20. 10.1038/ncb2210.
78. Scherr M., Venturini L., Battmer K., Schaller-Schoenitz M., Schaefer D., Dallmann I., et al. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res 2007, 35(22):e149. Epub 2007 Nov 19.
79. Kumar M.S., Erkeland S.J., Pester R.E., Chen C.Y., Ebert M.S., Sharp P.A., et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA. 2008, 105(10):3903-3908. Epub 2008 Feb 28. 10.1073/pnas.0712321105.
80. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137(6):1005-1017. 10.1016/j.cell.2009.04.021.
81. Trang P., Wiggins J.F., Daige C.L., Cho C., Omotola M., Brown D., et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011, 19(6):1116-1122. Epub 2011 Mar 22. 10.1038/mt.2011.48.
82. Krützfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438(7068):685-689. Epub 2005 Oct 30.
83. Ma L., Reinhardt F., Pan E., Soutschek J., Bhat B., Marcusson E.G., et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010, 28(4):341-347. Epub 2010 Mar 28. 10.1038/nbt.1618.
84. Brown B.D., Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009, 10(8):578-585.
85. Ma L., Young J., Prabhala H., et al. MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010, 12:247-256.
86. Saito Y., Liang G., Egger G., et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer cell 2006, 9:435-443.
87. Trompeter H.I., Abbad H., Iwaniuk K.M., Hafner M., Renwick N., Tuschl T., et al. MicroRNAs miR-17, miR-20a, and miR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One 2011, 6(1):e16138.
88. Guttilla I.K., White B.A. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 2009, 284(35):23204-23216. Epub 2009 Jul 1. 10.1074/jbc.M109.031427.
89. Gebeshuber C.A., Zatloukal K., Martinez J. MiR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009, 10:400-405.
90. Al-Nakhle H., Burns P., Cummings M., Hanby A., Hughes T., Satheesha S., et al. MiR-92 is a novel regulator of ERβ1 expression in breast cancer. Cancer Res 2009, 69(24 (Suppl. 3)):4-9. 10.1158/0008-5472.SABCS-09-4139.
91. Ivanovska I., Ball A.S., Diaz R.L., Magnus J.F., Kibukawa M., Schelter J.M., et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008, 28:2167-2174.
92. Kong W., Yang H., He L., Zhao J.J., Coppola D., Dalton W.S., et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008, 28:6773-6784. 10.1128/MCB.00941-08.
93. Nagpal N., Ahmad H.M., Molparia B., Kulshreshtha R. MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer. Carcinogenesis 2013, 4:2-9. Epub March 29, 2013. 10.1093/carcin/bgt107.
94. Luthra R., Singh R.R., Luthra M.G., Li Y.X., Hannah C., Romans A.M., et al. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene 2008, 27(52):6667-6678. Epub 2008 Jul 28. 10.1038/onc.2008.256.
95. Cascio S., D'Andrea A., Ferla R., Surmacz E., Gulotta E., Amodeo V., et al. MiR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol 2010, 224(1):242-249. 10.1002/jcp.22126.
96. Pandey D.P., Picard D. MiR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol 2009, 29(13):3783-3790. Epub 2009 May 4. 10.1128/MCB.01875-08.
97. Wang S., Bian C., Yang Z., Bo Y., Li J., Zeng L., et al. Zhao RC.miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 2009, 34(5):1461-1466.
98. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells. Oncogene. Author manuscript; available in PMC 2010 January 26.
99. Li X.F., Yan P.J., Shao Z.M. Down-regulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 2009, 28(44):3937-3948. Epub 2009 Aug 24. 10.1038/onc.2009.245.
100. Zhu S., Sachdeya M., Wu F., Lu Z., Mo Y.Y. Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene 2010, 29:1763-1772.
101. Li Q.Q., Chen Z.Q., Cao X.X., Xu J.D., Xu J.W., Chen Y.Y., et al. Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ 2011, 18(1):16-25. Epub 2010 Aug 27. 10.1038/cdd.2010.103.